Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week
Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, is set to provide important updates by the end of this week. These updates include:
1. Timelines for the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas.
2. Details on Tevogen AI, their proprietary artificial intelligence initiative aimed at reducing drug development costs, accelerating drug discovery, and delivering therapies to large patient populations.
3. Information on clinical and commercial manufacturing progress.
The company had previously forecasted approximately $1 billion in revenue for each therapeutic area in their respective launch years, with a 5-year combined estimate between $28 billion and $36 billion.
Tevogen Bio (Nasdaq: TVGN), una biotech specializzata in immunoterapia in fase clinica, è pronta a fornire aggiornamenti importanti entro la fine di questa settimana. Questi aggiornamenti includono:
1. Tempistiche per la previsione di fatturato precedentemente annunciata per le aree terapeutiche di Tevogen Oncology e Tevogen Specialty Care.
2. Dettagli su Tevogen AI, la loro iniziativa proprietaria di intelligenza artificiale mirata a ridurre i costi di sviluppo dei farmaci, accelerare la scoperta di nuovi farmaci e fornire terapie a grandi popolazioni di pazienti.
3. Informazioni sui progressi nella produzione clinica e commerciale.
L'azienda aveva precedentemente previsto un fatturato di circa 1 miliardo di dollari per ogni area terapeutica nei rispettivi anni di lancio, con una stima combinata di 5 anni tra 28 e 36 miliardi di dollari.
Tevogen Bio (Nasdaq: TVGN), una biotecnológica especializada en inmunoterapia en etapa clínica, está lista para proporcionar actualizaciones importantes a finales de esta semana. Estas actualizaciones incluyen:
1. Cronogramas para la previsión de ingresos previamente anunciada para las áreas terapéuticas de Tevogen Oncology y Tevogen Specialty Care.
2. Detalles sobre Tevogen AI, su iniciativa propia de inteligencia artificial destinada a reducir los costos de desarrollo de medicamentos, acelerar el descubrimiento de nuevos fármacos y ofrecer terapias a grandes poblaciones de pacientes.
3. Información sobre progresos en la fabricación clínica y comercial.
La empresa había pronosticado previamente aproximadamente 1 mil millones de dólares en ingresos para cada área terapéutica en sus respectivos años de lanzamiento, con una estimación combinada a 5 años entre 28 y 36 mil millones de dólares.
Tevogen Bio (Nasdaq: TVGN), 임상 단계의 전문 면역 치료 생명공학 회사가 이번 주 말까지 중요한 업데이트를 제공할 예정입니다. 이 업데이트에는:
1. Tevogen Oncology와 Tevogen Specialty Care 치료 영역에 대한 기존 수익 예측의 시간표가 포함됩니다.
2. 약물 개발 비용을 줄이고, 약물 발견을 가속화하며, 대규모 환자 집단에 치료법을 제공하기 위한 그들의 독점 인공지능 이니셔티브인 Tevogen AI에 대한 자세한 정보.
3. 임상 및 상업 생산 진행 상황에 대한 정보.
회사는 각 치료 영역의 출시 연도에 약 10억 달러의 수익을 예측했으며, 5년간의 총 예측치는 280억 달러에서 360억 달러 사이입니다.
Tevogen Bio (Nasdaq: TVGN), une biotechnologie spécialisée en immunothérapie en phase clinique, s'apprête à fournir d'importantes mises à jour d'ici la fin de cette semaine. Ces mises à jour incluent :
1. Calendriers pour les prévisions de revenus précédemment annoncées pour les domaines thérapeutiques de Tevogen Oncology et Tevogen Specialty Care.
2. Détails sur Tevogen AI, leur initiative d'intelligence artificielle propriétaire visant à réduire les coûts de développement de médicaments, à accélérer la découverte de médicaments et à fournir des thérapies à de larges populations de patients.
3. Informations sur les progrès de la fabrication clinique et commerciale.
L'entreprise avait précédemment prévu environ 1 milliard de dollars de revenus pour chaque domaine thérapeutique lors de leurs années de lancement respectives, avec une estimation combinée sur 5 ans entre 28 milliards et 36 milliards de dollars.
Tevogen Bio (Nasdaq: TVGN), ein biopharmazeutisches Unternehmen im Bereich der immuntherapeutischen Spezialität, wird bis Ende dieser Woche wichtige Updates bereitstellen. Diese Updates umfassen:
1. Zeitpläne für die zuvor angekündigte Umsatzprognose für die therapeutischen Bereiche Tevogen Oncology und Tevogen Specialty Care.
2. Details zu Tevogen AI, ihrem proprietären KI-Vorhaben, das darauf abzielt, die Kosten für die Arzneimittelentwicklung zu senken, die Arzneimittelentdeckung zu beschleunigen und Therapien an große Patientengruppen zu liefern.
3. Informationen über Fortschritte in der klinischen und kommerziellen Produktion.
Das Unternehmen hatte zuvor einen Umsatz von etwa 1 Milliarde Dollar für jeden therapeutischen Bereich in den jeweiligen Startjahren prognostiziert, mit einer 5-Jahres-Gesamtprognose zwischen 28 Milliarden und 36 Milliarden Dollar.
- Projected revenue of $1 billion for each therapeutic area (Oncology and Specialty Care) in their launch years
- 5-year combined revenue estimate between $28 billion and $36 billion
- Development of Tevogen AI to potentially reduce drug development costs and accelerate drug discovery
- None.
Insights
The announcement of revenue forecasts for Tevogen Bio's oncology and specialty care divisions is significant, projecting
The company's focus on off-the-shelf T cell therapeutics for infectious diseases and cancers positions it in a competitive but potentially lucrative market. The mention of Tevogen AI indicates a strategic move to leverage artificial intelligence for cost reduction and accelerated drug development, which could be a differentiator if successfully implemented.
Upcoming updates on clinical and commercial manufacturing will be important for assessing the company's ability to meet these projections. Investors should closely monitor these developments, as they will provide insights into Tevogen's operational readiness and potential timeline to market.
Tevogen Bio's approach using off-the-shelf, genetically unmodified T cell therapeutics is noteworthy in the competitive immunotherapy landscape. This technology potentially offers advantages in manufacturing scalability and cost-effectiveness compared to personalized cell therapies. The company's dual focus on infectious diseases and cancers provides diversification and multiple paths to market.
The integration of AI in drug development, if successful, could significantly enhance Tevogen's competitive position by reducing costs and accelerating timelines. This aligns with industry trends towards more efficient R&D processes. However, the success of AI in drug discovery is still evolving and its impact on Tevogen's pipeline remains to be seen.
Investors should pay close attention to upcoming clinical trial results and regulatory milestones, as these will be critical in validating the company's technology and revenue projections. The transition from clinical to commercial manufacturing will also be a key indicator of Tevogen's ability to deliver on its ambitious forecasts.
WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to provide further updates on the previously announced revenue forecast for Tevogen Oncology and Tevogen Specialty Care therapeutic areas by the end of this week. The revenue forecast for the two therapeutic areas is approximately
Tevogen Bio also plans to update shareholders on Tevogen AI, its proprietary artificial intelligence effort, designed to advance a mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations. In addition, Tevogen Bio will provide an update on clinical and commercial manufacturing.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is the expected revenue for Tevogen Bio's Oncology and Specialty Care areas in their launch years?
What is the 5-year combined revenue estimate for Tevogen Bio's Oncology and Specialty Care areas?
What is Tevogen AI and what is its purpose?
When will Tevogen Bio (TVGNW) provide updates on its revenue forecast and operational readiness?
